Key points are not available for this paper at this time.
Circulating tumor DNA (ctDNA) testing has emerged as a novel tool for cancer precision medicine. This study investigated the genomic profiling and clinical utility of ctDNA in metastatic prostate cancer.
Shiota et al. (Wed,) studied this question.